SWOG clinical trial number
SWOG-9336

A Phase III Comparison Between Concurrent Chemotherapy Plus Radiotherapy, and Concurrent Chemotherapy Plus Radiotherapy Followed by Surgical Resection of Stage IIIA (N2) Non-Small Cell Lung Cancer

Closed
Phase
Published
Abbreviated Title
Chemo/Surgical Resection of Stage IIIA (N2)/RT in NSCLC
Activated
05/15/1994
Closed
11/30/2001
Participants
Medical Oncologists

Research committees

Lung Cancer

Treatment

Cisplatin Etoposide Radiation Therapy Surgery

Eligibility Criteria Expand/Collapse

Single, newly diagnosed, primary lung parenchymal lesion of Stage IIIA (T1, 2 or 3) with ipsilateral positive mediastinal nodes (N2); Either measureable or evaluable dz by chest xray and/or contrast CT scan is allowed; a contrast CT scan of the thorax is required to complete the T and N staging; histologic (biopsy) or cytologic (needle aspiration or sputum) proof of non-small cell histology must be obtained and satisfy both of the following: adenocarcinoma, large cell carcinoma, squamous carcinoma or non-lobar and non-diffuse bronchoalveolar cell carcinoma AND documentation of non small cell carcinoma may originate from the mediastinal node biopsy or needle aspiration only if a distinct lung primary separate from the nodes is clearly evident on the CT scan; No prior chemo or RT for lung cancer; pt. must have adequate hemat., hepatic & renal function; no metastatic disease; pt. must be a candidate for potential future pulmonary resection; Karnofsky PS >=90% OR if PS is 70-80%, albumin must be >= .85 x ILLN and weight loss <=10% due to tumor; (refer to protocol for more specific criteria).

Publication Information Expand/Collapse

2009

Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomized controlled trial [PMID19632716]

KS Albain;RS Swann;VW Rusch;AT Turrisi;FA Shepherd;C Smith;Y Chen;RB Livingston;RH Feins;DR Gandara;WA Fry;G Darling;DH Johnson;MR Green;RC Miller;J Ley;WT Sause;JC Cox Lancet 374:379-386

2005

Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): Outcomes update of North American intergroup 0139 (RTOG 9309)

KS Albain;RS Swann;VR Rusch;AT Turrisi;FA Shepherd;CJ Smith;DR Gandara;DH Johnson;MR Green;RC Miller Proc of the ASCO, JCO 23(16S):624s (#7014)

2003

Phase III comparison of concurrent chemotherapy plus radiotherapy (CT/RT) and CT/RT followed by surgical resection for stage IIIA (pN2) non-small cell lung cancer (NSCLC): initial results from intergroup trial 0139 (RTOG 93-09).

KS Albain;CB Scott;VR Rusch;AT Turrisi;FA Shepherd;C Smith;DR Gandara;DH Johnson;MR Green;RC Miller Proc of the American Society of Clinical Oncology 22:621(#2497)

Other Clinical Trials

SWOG Clinical Trial Number
S2302

PRAGMATICA - LUNG: A PROSPECTIVE RANDOMIZED STUDY OF RAMUCIRUMAB (LY3009806; NSC 749128) PLUS PEMBROLIZUMAB (MK-3475; NSC 776864) VERSUS STANDARD OF CARE FOR PARTICIPANTS PREVIOUSLY TREATED WITH IMMUNOTHERAPY FOR STAGE IV OR RECURRENT NON-SMALL CELL LUNG CANCER
Research Committee(s)
Lung Cancer
Activated
03/06/2023
Accrual
63%
Open
Phase
SWOG Clinical Trial Number
A082002

A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy with or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
Research Committee(s)
Lung Cancer
Activated
12/21/2021
Open
Phase
SWOG Clinical Trial Number
CTSU/NRG-LU007

RAndomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
Research Committee(s)
Lung Cancer
Activated
08/17/2020
Open